clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Chlamydial Pneumonia D061387 2 associated lipids
Sacroiliitis D058566 1 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Renal Insufficiency D051437 8 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Liver Failure, Acute D017114 11 associated lipids
IgA Deficiency D017098 2 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Empyema, Pleural D016724 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacteremia D016470 9 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Eye Infections D015817 1 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Wound Infection D014946 12 associated lipids
Whooping Cough D014917 6 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urticaria D014581 13 associated lipids
Urination Disorders D014555 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urethritis D014526 9 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Ureteral Diseases D014515 3 associated lipids
Typhoid Fever D014435 2 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Tuberculosis D014376 20 associated lipids
Tooth Discoloration D014075 7 associated lipids
Tenosynovitis D013717 3 associated lipids
Syphilis D013587 6 associated lipids
Synovitis D013585 15 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Stomach Diseases D013272 7 associated lipids
Sporotrichosis D013174 3 associated lipids
Splenic Diseases D013158 5 associated lipids
Skin Ulcer D012883 6 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Sinusitis D012852 9 associated lipids
Shock, Septic D012772 11 associated lipids
Serositis D012700 1 associated lipids
Scrub Typhus D012612 3 associated lipids
Rosacea D012393 13 associated lipids
Rodent Diseases D012376 4 associated lipids
Rickettsia Infections D012282 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Radiation Injuries D011832 14 associated lipids
Pyelonephritis D011704 5 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Psoriasis D011565 47 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Butt AA Cervical adenitis due to Mycobacterium fortuitum in patients with acquired immunodeficiency syndrome. 1998 Am. J. Med. Sci. pmid:9427575
Feldman C et al. Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. 1997 Inflammation pmid:9429912
Stone GG et al. Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. 1996 Helicobacter pmid:9432314
McLaren A et al. The role of ranitidine bismuth citrate in significantly reducing the emergence of Helicobacter pylori strains resistant to antibiotics. 1997 Helicobacter pmid:9432317
Bardhan KD et al. Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. 1997 Helicobacter pmid:9432318
Takimoto T et al. The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients. 1997 Helicobacter pmid:9432334
Pieramico O et al. Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: a randomized trial. 1997 Helicobacter pmid:9432335
Pounder RE et al. Ranitidine bismuth citrate with clarithromycin for the eradication of Helicobacter pylori and for ulcer healing. 1997 Helicobacter pmid:9432341
Reisner BS et al. Electron microscopic analysis of Mycobacterium avium complex isolates exposed to ciprofloxacin, rifabutin, ethambutol and clarithromycin. 1997 Int. J. Tuberc. Lung Dis. pmid:9432376
Lerang F et al. Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy. 1997 Scand. J. Gastroenterol. pmid:9438318
Akiyama H et al. Biofilm formation of Staphylococcus aureus strains isolated from impetigo and furuncle: role of fibrinogen and fibrin. 1997 J. Dermatol. Sci. pmid:9438901
Bazzoli F and Pozzato P Therapy of H. pylori infection. 1997 J. Physiol. Pharmacol. pmid:9440054
Dixon JS et al. Ranitidine bismuth citrate plus clarithromycin for the eradication of H. pylori. 1997 J. Physiol. Pharmacol. pmid:9440055
Yatsunami J et al. Clarithromycin is a potent inhibitor of tumor-induced angiogenesis. 1997 Res Exp Med (Berl) pmid:9440137
Burman WJ et al. A retrospective comparison of clarithromycin versus rifampin in combination treatment for disseminated Mycobacterium avium complex disease in AIDS: clarithromycin decreases transfusion requirements. 1997 Int. J. Tuberc. Lung Dis. pmid:9441082
Suzuki K et al. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages. 1997 Int. J. Tuberc. Lung Dis. pmid:9441102
Gotoh A et al. Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori. 1997 Microbiol. Immunol. pmid:9444328
Mikamo H et al. Effects of long-term/low-dose clarithromycin on neutrophil count and interleukin-8 level in pyometra. 1998 Jan-Feb Chemotherapy pmid:9444409
Prattichizzo FA et al. [Carditis associated with Mycoplasma pneumoniae infection. Clinical aspects and therapeutic problems]. 1997 Minerva Cardioangiol pmid:9446067
Genné D et al. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9447898
Fennerty MB Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. 1998 Am. J. Gastroenterol. pmid:9448162
Forné M et al. Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. 1998 Am. J. Gastroenterol. pmid:9448170
Bermudez LE et al. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. 1998 Antimicrob. Agents Chemother. pmid:9449283
Sax L Bacterial pharyngitis in children. 1998 J Fam Pract pmid:9451356
Goujard C et al. Clarithromycin-resistant Mycobacterium avium strain in a clarithromycin-naive AIDS patient. 1998 Clin. Infect. Dis. pmid:9455532
Thornsberry C et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. 1997 Diagn. Microbiol. Infect. Dis. pmid:9458982
Holmberg SD et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. 1998 JAMA pmid:9459473
Briant C et al. Pericarditis as a manifestation of Lyme disease. 1997 J Emerg Nurs pmid:9460386
Misiewicz JJ et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. 1997 Gut pmid:9462204
Loo VG et al. In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. 1997 J. Antimicrob. Chemother. pmid:9462442
Hoffner SE et al. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. 1997 J. Antimicrob. Chemother. pmid:9462443
Torresani C et al. Clarithromycin versus doxycycline in the treatment of rosacea. 1997 Int. J. Dermatol. pmid:9466207
Preston SL et al. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. 1998 AIDS pmid:9468380
Tzivras M et al. One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer. 1997 Eur J Gastroenterol Hepatol pmid:9471024
Price J and Hamilton W Pragmatic eradication of H. pylori. 1997 Br J Gen Pract pmid:9474836
Hahn DL et al. Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma. 1998 Ann. Allergy Asthma Immunol. pmid:9475566
Cammarota G et al. Regression of a primary gastric MALT lymphoma with extensive antrum lesions by Helicobacter pylori eradication. 1997 Ital J Gastroenterol Hepatol pmid:9476192
Hotz J [Reflux disease of the gastrointestinal tract. Acute therapy and long-term care in daily practice. 2. Therapeutic procedure--diagnosis--therapy-diagram]. 1997 Fortschr. Med. pmid:9480263
Ridgway GL et al. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. 1997 J. Antimicrob. Chemother. pmid:9484871
Igea JM and Lázaro M Hypersensitivity reaction to clarithromycin. 1998 Allergy pmid:9491242
Hermon-Taylor J et al. Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease. 1998 BMJ pmid:9492675
Kondoh K and Hashiba M [Inhibitory effect of macrolide antibiotics on biofilm formation by Pseudomonas aeruginosa]. 1998 Nippon Jibiinkoka Gakkai Kaiho pmid:9493436
Boixeda de Miquel D [Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer]. 1997 Rev Esp Enferm Dig pmid:9494374
Pérez Mota A et al. Helicobacter pylori, efficacy of the new triple therapy in six and twelve-day schedules. 1997 Rev Esp Enferm Dig pmid:9494375
Payen MC et al. [Manifestations, diagnosis and treatment of non-tuberculous mycobacterial infections in patients with HIV infection]. 1997 Rev Mal Respir pmid:9496599
Kusuhara H et al. Evaluation of combined antibiotic-omeprazole therapies in Helicobacter pylori-infected Mongolian gerbils. 1998 J. Gastroenterol. pmid:9497215
Dubois A et al. Cure of Helicobacter pylori infection by omeprazole-clarithromycin-based therapy in non-human primates. 1998 J. Gastroenterol. pmid:9497216
Hocqueloux L et al. Pulmonary Mycobacterium avium complex disease without dissemination in HIV-infected patients. 1998 Chest pmid:9498982
Ziering W and McElvaine P Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis. 1998 Jan-Feb Infection pmid:9505188
Rosina P et al. Fixed drug eruption from clarithromycin. 1998 Contact Derm. pmid:9506224